SCHEMBL10328652

SCHEMBL10328652

CCC(C)c1coc(C(=O)O)cc1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
KDM4E B2RXH2 3/20 0.36
USP2 O75604 1/20 0.36
CSNK2A2 P19784 1/20 0.36
PTGS1 P23219 1/20 0.36
CSNK2B P67870 1/20 0.36
CSNK2A1 P68400 1/20 0.36
CSNK2A3 Q8NEV1 1/20 0.36
GPR35 Q9HC97 2/20 0.35
HDAC4 P56524 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
TSHR P16473 1/20 0.34
AKR1B1 P15121 1/20 0.34
RXRA P19793 1/20 0.34
PTGER4 P35408 1/20 0.33
LMNA P02545 1/20 0.33
RECQL P46063 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10328545 0.82 FABP3 (0.41) ALDH1A1KDM4EUSP2CSNK2A2PTGS1
SCHEMBL3334784 0.71 PTPN1 (0.40) ALDH1A1NPC1RAB9AKDM4EUSP2
SCHEMBL10328631 0.71 ALDH1A1 (0.45) ALDH1A1KDM4EUSP2CSNK2A2PTGS1
SCHEMBL10032704 0.71 KDM4E (0.42) ALDH1A1KDM4EUSP2CSNK2A2PTGS1
SCHEMBL10328529 0.70 GPR35 (0.34) ALDH1A1KDM4EUSP2CSNK2A2PTGS1
SCHEMBL10328613 0.69 ALDH1A1 (0.40) ALDH1A1NPC1RAB9AKDM4EUSP2
SCHEMBL10328546 0.69 PDE2A (0.41) ALDH1A1KDM4EGPR35TSHRLMNA
SCHEMBL3333978 0.69 GPR35 (0.43) ALDH1A1PTGS1GPR35PTGER4GRM8
SCHEMBL11636077 0.69 PTGER4 (0.46) ALDH1A1NPC1RAB9AKDM4ERXRA
SCHEMBL1171093 0.69 DAO (0.50) KDM4ETYR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748483-B2 Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome SANOFI (FR) 2014-06-10 US disclosed
US-8748483-B2 Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome SANOFI (FR) 2014-06-10 US disclosed
EP-2120923-B1 USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME SANOFI SA (FR) 2012-07-18 EP disclosed
US-20100144862-A1 USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME SANOFI-AVENTIS (FR) 2010-06-10 US disclosed
US-20100144862-A1 USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME SANOFI-AVENTIS (FR) 2010-06-10 US disclosed
WO-2008086949-A1 USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME SANOFI-AVENTIS (FR) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144862-A1 USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME PC, PCK1, PDK4 ALDH1A1 951/4885NPC1 1500/4885RAB9A 3665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.